Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data provide valuable insights for everyday practice. A long-term goal of systemic psoriasis therapy is to erase the inflammatory memory and thus achieve a sustainable cure. Several research projects have therefore focused on tissue-resident memory T-cells.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle